Crossmark

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis

Crossref DOI link: https://doi.org/10.1007/s10549-016-3798-8

Published Online: 2016-04-22

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lavaud, P.

Rousseau, B.

Ajgal, Z.

Arrondeau, J.

Huillard, O.

Alexandre, J.

Hulin, A.

Goldwasser, F.
License Information

Text and Data Mining valid from 2016-04-22